SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘R5’

On:  Thursday, 7/11/19, at 4:17pm ET   ·   Accession #:  1213900-19-12524   ·   File #:  333-232332

Previous ‘S-1’:  ‘S-1’ on 6/25/19   ·   Next:  ‘S-1’ on 8/1/19   ·   Latest:  ‘S-1/A’ on 10/27/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/11/19  DelMar Pharmaceuticals, Inc.      S-1/A                 71:7.9M                                   Edgar Agents LLC/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 1 to Form S-1                         HTML   1.11M 
 2: EX-23.1     Consent of Ernst & Young, LLP                       HTML     19K 
 9: R1          Document and Entity Information                     HTML     34K 
10: R2          Consolidated Condensed Interim Balance Sheets       HTML     90K 
11: R3          Consolidated Condensed Interim Balance Sheets       HTML     41K 
                (Parenthetical)                                                  
12: R4          Consolidated Condensed Interim Statements of Loss   HTML     63K 
                and Comprehensive Loss                                           
13: R5          Consolidated Statements of Changes in               HTML    112K 
                Stockholders' Equity                                             
14: R6          Consolidated Condensed Interim Statements of Cash   HTML     84K 
                Flows                                                            
15: R7          Going Concern, Nature of Operations, and Corporate  HTML     40K 
                History                                                          
16: R8          Significant Accounting Policies                     HTML     81K 
17: R9          Valent Technologies, LLC                            HTML     28K 
18: R10         Derivative Liability                                HTML     61K 
19: R11         Stockholders' Equity                                HTML    227K 
20: R12         Financial Instruments                               HTML     36K 
21: R13         Related Party Transactions                          HTML     22K 
22: R14         Current and Deferred Income Taxes                   HTML     37K 
23: R15         Commitments and Contingencies                       HTML     25K 
24: R16         Supplementary Statement of Cash Flows Information   HTML     31K 
25: R17         Financial Risk Management                           HTML     34K 
26: R18         Subsequent Events                                   HTML     32K 
27: R19         Significant Accounting Policies (Policies)          HTML    129K 
28: R20         Significant Accounting Policies (Tables)            HTML     25K 
29: R21         Derivative Liability (Tables)                       HTML     57K 
30: R22         Stockholders' Equity (Tables)                       HTML    202K 
31: R23         Financial Instruments (Tables)                      HTML     28K 
32: R24         Current and Deferred Income Taxes (Tables)          HTML     47K 
33: R25         Supplementary Statement of Cash Flows Information   HTML     30K 
                (Tables)                                                         
34: R26         Financial Risk Management (Tables)                  HTML     33K 
35: R27         Going Concern, Nature of Operations, and Corporate  HTML     37K 
                History (Details)                                                
36: R28         Significant Accounting Policies (Details)           HTML     30K 
37: R29         Significant Accounting Policies (Details Textual)   HTML     45K 
38: R30         Valent Technologies, LLC (Details)                  HTML     49K 
39: R31         Derivative Liability (Details)                      HTML     37K 
40: R32         Derivative Liability (Details 1)                    HTML     41K 
41: R33         Derivative Liability (Details Textual)              HTML     71K 
42: R34         Stockholders' Equity (Details)                      HTML    100K 
43: R35         Stockholders' Equity (Details 1)                    HTML     30K 
44: R36         Stockholders' Equity (Details 2)                    HTML     37K 
45: R37         Stockholders' Equity (Details 3)                    HTML     40K 
46: R38         Stockholders' Equity (Details 4)                    HTML    118K 
47: R39         Stockholders' Equity (Details 5)                    HTML     38K 
48: R40         Stockholders' Equity (Details 6)                    HTML     30K 
49: R41         Stockholders' Equity (Details 7)                    HTML     51K 
50: R42         Stockholders' Equity (Details 8)                    HTML     35K 
51: R43         Stockholders' Equity (Details 9)                    HTML     58K 
52: R44         Stockholders' Equity (Details 10)                   HTML     90K 
53: R45         Stockholders' Equity (Details 11)                   HTML     33K 
54: R46         Financial Instruments (Details)                     HTML     28K 
55: R47         Related Party Transactions (Details)                HTML     23K 
56: R48         Current and Deferred Income Taxes (Details)         HTML     47K 
57: R49         Current and Deferred Income Taxes (Details 1)       HTML     44K 
58: R50         Current and Deferred Income Taxes (Details          HTML     46K 
                Textual)                                                         
59: R51         Commitments and Contingencies (Details)             HTML     27K 
60: R52         Stockholders' Equity (Details Textual)              HTML     91K 
61: R53         Stockholders' Equity (Details Textual 1)            HTML     66K 
62: R54         Stockholders' Equity (Details Textual 2)            HTML     52K 
63: R55         Stockholders' Equity (Details Textual 3)            HTML     46K 
64: R56         Supplementary Statement of Cash Flows Information   HTML     43K 
                (Details)                                                        
65: R57         Financial Risk Management (Details)                 HTML     27K 
66: R58         Financial Risk Management (Details 1)               HTML     28K 
67: R59         Financial Risk Management (Details Textual)         HTML     48K 
68: R60         Subsequent Events (Details)                         HTML     51K 
70: XML         IDEA XML File -- Filing Summary                      XML    133K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 3: EX-101.INS  XBRL Instance -- dmpi-20190331                       XML   2.20M 
 5: EX-101.CAL  XBRL Calculations -- dmpi-20190331_cal               XML    142K 
 6: EX-101.DEF  XBRL Definitions -- dmpi-20190331_def                XML    703K 
 7: EX-101.LAB  XBRL Labels -- dmpi-20190331_lab                     XML   1.14M 
 8: EX-101.PRE  XBRL Presentations -- dmpi-20190331_pre              XML    897K 
 4: EX-101.SCH  XBRL Schema -- dmpi-20190331                         XSD    211K 
71: ZIP         XBRL Zipped Folder -- 0001213900-19-012524-xbrl      Zip    171K 


‘R5’   —   Consolidated Statements of Changes in Stockholders’ Equity


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.19.2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common stock
Additional paid-in capital
Accumulated other comprehensive income
Preferred stock
Warrants
Accumulated deficit
Total
Balance at Jun. 30, 2016 $ 1,119 $ 28,843,173 $ 21,178 $ 6,572,785 $ 1,658,382 $ (32,237,859) $ 4,858,778
Balance, Shares at Jun. 30, 2016 1,118,702            
Issuance of shares and warrants - net of issue costs $ 277 4,981,093 2,950,737 7,932,107
Issuance of shares and warrants - net of issue costs, shares 276,923            
Shares issued for services $ 6 563,994 564,000
Shares issued for services, shares 6,000            
Warrants issued for services 81,602 81,602 [1]
Reclassification of stock option liability 260,969 260,969
Warrants exercised for cash $ 24 908,399 (120,147) 788,276
Warrants exercised for cash, shares 23,953            
Cashless exercise of warrants 5,159   5,159
Cashless exercise of warrants, shares 59            
Amendment of warrants (note 4) 53,006 53,006
Stock option expense 124,747 124,747
Conversion of Series B preferred stock to common stock $ 5 147,370 (147,375)
Conversion of Series B preferred stock to common stock, shares 5,281            
Series A preferred cash dividend (note 3) (8,356) (8,356)
Series B preferred stock dividend $ 20 790,434 (790,454)
Series B preferred stock dividend, shares 20,045            
Loss for the year           (8,081,764) (8,081,764)
Balance at Jun. 30, 2017 $ 1,451 36,678,344 21,178 6,425,410 4,570,574 (41,118,433) 6,578,524
Balance, Shares at Jun. 30, 2017 1,450,963            
Issuance of shares and warrants - net of issue costs $ 800 6,191,785     2,752,751  
Issuance of shares and warrants - net of issue costs, shares 800,000            
Shares issued for services 4,821      
Shares issued for services, shares 407            
Warrants issued for services     155,204  
Warrants exercised for cash $ 25 312,475      
Warrants exercised for cash, shares 25,000            
Stock option expense 430,673      
Performance stock unit expense            
Series B preferred stock dividend $ 15 142,343     (142,358)  
Series B preferred stock dividend, shares 14,881            
Loss for the year             (8,761,061)
Balance at Mar. 31, 2018 $ 2,291 43,760,441     7,478,529 (50,028,119)  
Balance, Shares at Mar. 31, 2018 2,291,251            
Balance at Jun. 30, 2017 $ 1,451 36,678,344 21,178 6,425,410 4,570,574 (41,118,433) 6,578,524
Balance, Shares at Jun. 30, 2017 1,450,963            
Issuance of shares and warrants - net of issue costs $ 800 5,371,693 3,572,843 8,945,336
Issuance of shares and warrants - net of issue costs, shares 800,000            
Shares issued for services $ 1 8,581 8,582
Shares issued for services, shares 863            
Warrants issued for services 192,400 192,400 [1]
Warrants exercised for cash $ 25 418,810 (106,335) 312,500
Warrants exercised for cash, shares 25,000            
Stock option expense 495,925 495,925
Performance stock unit expense   48,624         48,624
Series A preferred cash dividend (note 3) (8,356) (8,356)
Series B preferred stock dividend $ 20 176,216 (176,236)
Series B preferred stock dividend, shares 19,841            
Loss for the year (11,138,312) (11,138,312)
Balance at Jun. 30, 2018 $ 2,297 43,198,193 21,178 6,425,410 8,229,482 (52,441,337) 5,435,223
Balance, Shares at Jun. 30, 2018 2,296,667            
Balance at Dec. 31, 2017 $ 2,261 43,259,228     7,321,844 (47,046,347)  
Balance, Shares at Dec. 31, 2017 2,260,884            
Shares issued for services 4,821      
Shares issued for services, shares 407            
Warrants issued for services     156,685  
Warrants exercised for cash $ 25 312,475      
Warrants exercised for cash, shares 25,000            
Stock option expense 137,296      
Series B preferred stock dividend $ 5 46,621     (46,626)  
Series B preferred stock dividend, shares 4,960            
Balance at Mar. 31, 2018 $ 2,291 43,760,441     7,478,529 (50,028,119)  
Balance, Shares at Mar. 31, 2018 2,291,251            
Balance at Jun. 30, 2018 $ 2,297 43,198,193 $ 21,178 $ 6,425,410 8,229,482 (52,441,337) 5,435,223
Balance, Shares at Jun. 30, 2018 2,296,667            
Issuance of shares and warrants - net of issue costs $ 297 2,920,695     (2,210,697)  
Issuance of shares and warrants - net of issue costs, shares 296,667            
Shares issued for services $ 2 10,267      
Shares issued for services, shares 2,269            
Warrants issued for services     36,534  
Stock option expense 355,388      
Conversion of Series B preferred stock to common stock $ 10 279,041      
Conversion of Series B preferred stock to common stock, shares 10,000            
Performance stock unit expense 183,205     183,205
Series B preferred stock dividend $ 14 75,463     (75,477)  
Series B preferred stock dividend, shares 14,430            
Loss for the year             (5,465,486)
Balance at Mar. 31, 2019 $ 2,620 47,022,252     6,055,319 (57,988,567) 1,259,161
Balance, Shares at Mar. 31, 2019 2,620,033            
Balance at Dec. 31, 2018 $ 2,614 46,851,817     6,046,587 (56,299,291)  
Balance, Shares at Dec. 31, 2018 2,614,342            
Issuance of shares and warrants - net of issue costs (16,186)      
Shares issued for services $ 1 3,512      
Shares issued for services, shares 956            
Warrants issued for services     8,732  
Stock option expense 99,735      
Performance stock unit expense 60,177      
Series B preferred stock dividend $ 5 23,197     (23,202)  
Series B preferred stock dividend, shares 4,735            
Balance at Mar. 31, 2019 $ 2,620 $ 47,022,252     $ 6,055,319 $ (57,988,567) $ 1,259,161
Balance, Shares at Mar. 31, 2019 2,620,033            
[1] Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below.
Top
Filing Submission 0001213900-19-012524   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 2:26:13.1pm ET